Sunovion, a Marlborough pharmaceutical company, has won Canadian regulatory approval for a drug treating episodes in those with Parkinson’s disease.
Sunovion, which announced the approval Monday, secured U.S. Food and Drug Administration approval in May. The drug, KYNMOBI, is the first drug dissolving under the tongue to treat Parkinson’s to win regulatory approval, according to Sunovion.
KYNMOBI will be made available in pharmacies across Canada as quickly as possible, Sunovion said.
The sublingual drug is used to treat what’s known as OFF episodes for Parkinson’s patients, when they experience symptoms like tremor or difficulty walking. In trials, Sunovion said it found those treated with KYNMOBI experienced significant improvements in motor symptoms within 30 minutes.
More than 17,000 Massachusetts residents have Parkinson’s, according to Sunovion, and nearly 1 million nationwide, according to the Parkinson’s Foundation.
